CMV Seropositivity and Viremia Drive T-Cell Reconstitution after CD34-Selected Allogeneic HCT Christina Cho, Patrick Hilden, Ioannis Politikos, Taylor.

Slides:

Advertisements

Similar presentations

Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective.

Advertisements

The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,

How to Treat MDS without Stem Cell Transplantation

Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Feasible Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) after Myeloablative.

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

Fludarabine-Based Conditioning Secures Engraftment of Second Hematopoietic Stem Cell Allografts (HSCT) in the Treatment of Initial Graft Failure Joseph.

Vaccination of Children following Allogeneic Stem Cell Transplantation

T Cell–Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission.

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

A Response Adapted Approach to Induction Treatment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Gunjan L. Shah,

Allogeneic Stem Cell Transplantation in Myelofibrosis

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Double Unit Cord Blood Transplantation (dCBT) Progression-Free Survival (PFS) is Unaffected by Grade III-IV Acute Graft-Versus-Host Disease (aGVHD) and.

Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Immune-Mediated Hemolytic Anemia (IMHA) and Immune Thrombocytopenia (ITP) after Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Standardized CD3+ Cell Dose for Allogeneic Peripheral Blood Stem Cell Transplant (PBSCT): An Interim Analysis Muhammad Omer Jamil, MD, Ayman Saad, MD,

Combining the Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Provides a Comprehensive Prognostic Model for.

Serious Infection Risk and Immune Recovery after Double-Unit Cord Blood Transplantation Without Antithymocyte Globulin Craig Sauter, Michelle Abboud,

Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double- Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin

High Progression-Free Survival (PFS) in Adult Double Unit Cord Blood (dCB) Transplant Recipients with High Risk Disease after a Novel Intermediate Intensity.

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord.

Outcomes with Pre-Emptive Rituximab (pre-R) Treatment for Epstein-Barr Viremia (EBV) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Tania.

Recipient CMV Seropositivity & Viremia is Associated with the Development of Cord Blood (CB) Derived CD8 + Effectors & Effector Memory Cells in Adults.

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

The Role of Post-Remission Chemotherapy before T-Cell Depleted Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia in First Complete Remission

Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous.

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide.

More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes Without Adding Serious Toxicity When Compared to Fludarabine/Melphalan.

Biology of Blood and Marrow Transplantation

John R. Wingard, M. D. , Alan K. Leahigh, Dennis Confer, M. D

Enrico Velardi, Jennifer J

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Biology of Blood and Marrow Transplantation

B Cells and Transplantation: An Educational Resource

Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe Shahram.

Infections Are the Major Cause of Non Relapse Mortality (NRM) after T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation for Advanced.

Graft-Versus Host Disease (GVHD Status and Severity Mediate Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a 1-Year Landmark.

Long-Term Prognosis Among 1-Year Survivors of Ex Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation: A Landmark Analysis Christina.

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

Disease Progression is Main Barrier to Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Members of the Intestinal Microbiota Are Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Jonathan U. Peled, MD, PhD,

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Infection Prevention - Visitors and the Best of Intentions

Intestinal Microbiota Injury during Allo-Hct is Generalizable across Transplantation Centers and is Associated with Increased Mortality, Broad-Spectrum.

Early Results of Phase II Study Using OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HCT-TMA) Samer.

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Biology of Blood and Marrow Transplantation

Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa Barbara.

Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes Bartlomiej M. Getta, Ashwin Kishtagari,

Clinical Strategies to Enhance Posttransplant Immune Reconstitution

Autoimmune Hemolysis (AH) & Immune Thrombocytopenic Purpura (ITP) after Cord Blood Transplantation (CBT) May be Life-Threatening & Warrant Early Therapy.

Comparison of T Cell Subset Recovery after Cord Blood and CD34-Selected Pbsc Transplantation Christina Cho, Ioannis Politikos, Patrick Hilden, Taylor.

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50.

Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation

Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving.

Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.

Cytomegalovirus Infection after CD34+-Selected Hematopoietic Cell Transplantation Yao-Ting Huang, Dionysios Neofytos, Julia Foldi, Seong Jin Kim, Molly.

Miguel-Angel Perales, Machaon Bonafede, Qian Cai, Phillip M

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation Nikhil Dole, Nathan Luebbering, Nicholas.

ATG16L1 Prevents Lethal T-Cell Alloreactivity Mediated By Dendritic Cells Yusuke Shono, MD, PhD, Vanessa Hubbard-Lucey, PhD, Katie Maurer, Anne Mary Dickinson,

Early Fluid Overload is a Serious Toxicity Associated with an Increased Risk of Non- Relapse Mortality after Ex-Vivo CD34-Selected Allogeneic Hematopoietic.

Biology of Blood and Marrow Transplantation

Presentation transcript:

CMV Seropositivity and Viremia Drive T-Cell Reconstitution after CD34-Selected Allogeneic HCT Christina Cho, Patrick Hilden, Ioannis Politikos, Taylor Borrill, Cristi Ciolino, Sean M. Devlin, Molly Maloy, Katherine Smith, Sergio A. Giralt, Richard J. O'Reilly, Marcel R.M. van den Brink, Miguel-Angel Perales Biology of Blood and Marrow Transplantation Volume 23, Issue 3, Pages S162-S163 (March 2017) DOI: 10.1016/j.bbmt.2016.12.344 Copyright © 2016 Terms and Conditions

Figure 1 T-cell subsets at 120 ± 30 days post-TCD PBSCT by CMV serostatus and viremia within 60 days of transplant. Biology of Blood and Marrow Transplantation 2017 23, S162-S163DOI: (10.1016/j.bbmt.2016.12.344) Copyright © 2016 Terms and Conditions

Figure 2 Total CD8 cells by CMV serostatus and viremia within 60 days of TCD PBSCT. Biology of Blood and Marrow Transplantation 2017 23, S162-S163DOI: (10.1016/j.bbmt.2016.12.344) Copyright © 2016 Terms and Conditions

Figure 3 CD8 effector memory cells by CMV serostatus and viremia within 60 days of TCD PBSCT. Biology of Blood and Marrow Transplantation 2017 23, S162-S163DOI: (10.1016/j.bbmt.2016.12.344) Copyright © 2016 Terms and Conditions